These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29902719)

  • 1. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
    Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
    Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
    Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
    Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
    J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
    Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
    Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
    Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
    Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
    Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
    Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
    Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
    Li S; Guo C; Zhao H; Tang Y; Lan M
    Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible inhibitors of the epidermal growth factor receptor: thienopyrimidine core with α,β-unsaturated amide side chain.
    Yang XL; Wang TC; Lin S; Fan HX
    Arch Pharm (Weinheim); 2014 Aug; 347(8):552-8. PubMed ID: 24917121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
    Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
    Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
    Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.